首页> 外文期刊>Chemico-biological interactions >A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma b
【24h】

A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma b

机译:一种新型的体外系统,即集成的离散多器官细胞培养(IdMOC)系统,用于评估人的药物毒性:他莫昔芬对来自五个主要器官和MCF-7腺癌的正常人细胞的比较细胞毒性b

获取原文
获取原文并翻译 | 示例
           

摘要

In vitro assays involving primary cells are used routinely to evaluate organ-specific toxic effects, for instance, the use of primary hepatocytes to evaluate hepatotoxicity. A major drawback of an in vitro system is the lack of multiple organ interactions as observed in a whole organism. A novel cell culture system, the integrated discrete multiorgan cell culture system (IdMOC), is described here. The IdMOC is based on the "wells within a well" concept, consisting of a cell culture plate with larger, containing wells, within each of which are multiple smaller wells. Cells from multiple organs can be cultured initially in the small wells (one organ per well, each in its specialized medium). On the day of toxicity testing, a volume of drug-containing medium is added to the containing well to flood all inner wells, thereby interconnecting all the small wells. After testing, the overlying medium is removed and each cell type is evaluated for toxicity using appropriate endpoints. We report here the application of IdMOC in the evaluation of the cytotoxicity of tamoxifen, an anticancer agent with known human toxicity, on primary cells from multiple human organs: liver (hepatocytes), kidney (kidney cortical cells), lung (small airway epithelial cells), central nervous system (astrocytes), blood vessels (aortic endothelial cells) as well as the MCF-7 human breast adenocarcinoma cells. IdMOC produced results that can be used for the quantitative evaluation of its anticancer effects (i.e., cytotoxicity towards MCF-7 cells) versus its toxicity toward normal organs (i.e., liver, kidney, lung, CNS, blood vessels).
机译:通常使用涉及原代细胞的体外测定来评估器官特异性毒性作用,例如,使用原代肝细胞来评估肝毒性。体外系统的主要缺点是,如在整个生物体内观察到的那样,缺乏多种器官的相互作用。本文介绍了一种新型的细胞培养系统,即集成的离散多器官细胞培养系统(IdMOC)。 IdMOC基于“孔内孔”的概念,该概念由具有较大且包含孔的细胞培养板组成,每个孔内有多个较小的孔。最初可以在小孔中培养来自多个器官的细胞(每孔一个器官,每个在其专门培养基中培养)。在毒性测试的当天,将一定量的含药培养基添加到容纳孔中,以淹没所有内部孔,从而互连所有小孔。测试后,除去上面的培养基,并使用适当的终点评估每种细胞类型的毒性。我们在此报告IdMOC在评估他莫昔芬(一种具有已知人类毒性的抗癌药)对来自多个人体器官的原代细胞(肝(肝细胞),肾脏(肾皮质皮层细胞),肺(小气道上皮细胞)的细胞毒性)中的应用),中枢神经系统(星形细胞),血管(主动脉内皮细胞)以及MCF-7人乳腺腺癌细胞。 IdMOC产生的结果可用于定量评估其抗癌作用(即对MCF-7细胞的细胞毒性)与对正常器官(即肝,肾,肺,中枢神经系统,血管)的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号